Gain Therapeutics (GANX) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rallybio (RLYB) has outperformed Gain Therapeutics (GANX) over the past year, gaining 208.4% versus a loss of 62.4%. Over five years, RLYB leads with a -85.3% price change compared with -87.3% for GANX. Gain Therapeutics is the larger company by market cap ($44.5 million vs $43.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GANX | RLYB |
|---|---|---|
| Share price | $0.9994 | $15.47 |
| Market cap | $44.50M | $43.32M |
| 1-day change | -4.82% | -0.32% |
| YTD return | -68.96% | +181.89% |
| 1-year return | -62.43% | +208.41% |
| 5-year return | -87.27% | -85.29% |
| P/E ratio (TTM) | — | 3.36 |
| EPS (TTM) | $-0.42 | $4.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $858.00K |
| Revenue growth (YoY) | — | +34.91% |
| Net income (latest FY) | $-20.16M | $-8.98M |
| Operating margin | — | -3853.61% |
| Net margin | — | -1046.39% |
| 52-week high | $4.34 | $35.15 |
| 52-week low | $0.94 | $7.34 |
| Distance from 52-week high | -76.97% | -55.99% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +620.43% | — |
| Average volume | 550.22K | 10.14K |
| Shares outstanding | 44.53M | 2.80M |
| Employees | 20 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed GANX by 270.8 percentage points over the past year.
About Gain Therapeutics
GANX stock →Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
GANX vs RLYB FAQ
Which is bigger, Gain Therapeutics or Rallybio?
Gain Therapeutics (GANX) is larger, with a market capitalization of $44.50M compared with $43.32M for Rallybio (RLYB).
Which stock has performed better over the past year, GANX or RLYB?
RLYB returned +208.41% over the past 12 months, compared with -62.43% for GANX (price return, excluding dividends). Past performance does not predict future results.
Are Gain Therapeutics and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.